# EDGAR Filing Document

**Accession Number:** 0001095981
**File Stem:** 0001193125-25-186490
**Filing Date:** 2025-8
**Character Count:** 49768
**Document Hash:** 588c568baac82328ab0d0a3760f44b91
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-186490.hdr.sgml**: 20250822

**ACCESSION NUMBER**: 0001193125-25-186490

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 18

**FILED AS OF DATE**: 20250822

**DATE AS OF CHANGE**: 20250822

**EFFECTIVENESS DATE**: 20250822

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PLUS THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001095981
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 330827593
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289822
- **FILM NUMBER:** 251247264

**BUSINESS ADDRESS:**
- **STREET 1:** 4200 MARATHON BLVD.
- **STREET 2:** SUITE 200
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78756
- **BUSINESS PHONE:** 737.255.7194

**MAIL ADDRESS:**
- **STREET 1:** 4200 MARATHON BLVD.
- **STREET 2:** SUITE 200
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78756

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYTORI THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20050712

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MACROPORE INC
- **DATE OF NAME CHANGE:** 20010320

**As filed with the Securities and Exchange Commission on August 22, 2025** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## PLUS THERAPEUTICS, INC.
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **33-0827593** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **2710 Reed Road, Suite 160**<br> **Houston, Texas** | **77002** |
| **(Address of Principal Executive Offices)** | **(Zip Code)** |

---

**Fifth Amended and Restated Plus Therapeutics, Inc. 2020 Stock Incentive Plan** 

**Plus Therapeutics, Inc. 2015 New Employee Incentive Plan** 

**(Full title of the Plans)** 

**Marc H. Hedrick, M.D.** 

**President and Chief Executive Officer** 

**Plus Therapeutics, Inc.** 

**2710 Reed Road, Suite 160** 

**Houston, Texas 77002** 

**(737) 255-7194** 

**(Name, address and telephone number of agent for service)** 

***With copies to:***

**David E. Danovitch** 

**Aaron M. Schleicher** 

**Sullivan & Worcester LLP** 

**1251 Avenue of the Americas** 

**New York, New York 10020** 

**(212) 660-3060** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 under the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
|  Large accelerated filer | ☐ | Accelerated filer | ☐ |
|  Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

------

**EXPLANATORY NOTE** 

This Registration Statement (the "Registration Statement") registers an aggregate of 20,075,000 additional shares of common stock, par value $0.001 per share (the "Common Stock") of Plus Therapeutics, Inc. (the "Registrant"), consisting of (i) 20,000,000 shares of Common Stock issuable pursuant to the Fifth Amended and Restated Plus Therapeutics, Inc. 2020 Stock Incentive Plan (the "2020 Stock Incentive Plan"), representing an increase of 20,000,000 shares of Common Stock reserved for issuance under the 2020 Stock Incentive Plan, as a result of an amendment thereto, which was adopted by the board of directors (the "Board") of the Registrant on July 17, 2025 and approved by the Registrant's stockholders at the Annual Meeting of Stockholders held on August 7, 2025; and (ii) 75,000 shares of Common Stock issuable pursuant to the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan (as amended, the "2015 Plan"), representing an increase of 75,000 shares of Common Stock reserved for issuance under the 2015 Plan, as a result of an amendment thereto, which was adopted by the Board on June 6, 2024. Pursuant to General Instruction E to Form S-8 under the Securities Act of 1933, as amended, the contents of the Registrant's registration statements on Form S-8 filed with the U.S. Securities and Exchange Commission (the "Commission") on March 15, 2016 (Registration No. 333-210211), March 9, 2018 (Registration No. 333-223566), June 30, 2020 (Registration No. 333-239548) and on August 23, 2024 (Registration No. 333-281758) are incorporated by reference and made part of this Registration Statement. Any items in such registration statements not expressly changed hereby shall be as set forth in such registration statements.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3. Incorporation of Documents by Reference.** 

The following documents filed by Registrant with the Commission are hereby incorporated by reference in this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Registrant's Annual Report on Form 10-K for the year ended
December 31, 2024 (filed with the Commission on [March 31, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1095981/000095017025047698/pstv-20241231.htm)) and the Amendment to the
Registrant's Annual Report on Form 10-K for the year ended December 
31, 2024 (filed with the Commission on [April 30, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1095981/000095017025061028/pstv-20241231.htm));

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) all other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Securities Exchange
Act of 1934 (the "Exchange Act") since the end of the fiscal year covered by the document referred to in (a) above (other than the portions of those documents not deemed to be filed); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the description of the Registrant's Common Stock contained in [Exhibit 4.1](http://www.sec.gov/Archives/edgar/data/1095981/000156459020014165/pstv-ex41_202.htm) to its Annual Report on Form 10-K for the fiscal year ended December 
31, 2024, filed with the Commission on [March 31, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1095981/000095017025047698/pstv-20241231.htm) (File No. 001-34375).

All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or that deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of the filing of such documents.

Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

------

**Item 8. Exhibits.** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  | | | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |
| **Exhibit<br>Number** | <br>**Description** |<br>**Filed<br>Herewith** |<br>**Form** | **File Number** | **Exhibit** | **Filing Date** |
| 5.1 | [Opinion of Sulivan & Worcester LLP](d19333dex51.htm) | X |  |  |  |  |
| 23.1 | [Opinion of Sullivan & Worcester LLP (included in Exhibit 5.1)](d19333dex51.htm) | X |  |  |  |  |
| 23.2 | [Consent of Independent Registered Public Accounting Firm](d19333dex232.htm) | X |  |  |  |  |
| 24.1 | [Power of Attorney (included on the signature page to this Registration Statement)](#sig) | X |  |  |  |  |
| 99.1 | [Fifth Amended and Restated Plus Therapeutics, Inc. 2020 Stock Incentive Plan](http://www.sec.gov/Archives/edgar/data/1095981/000095017025108874/pstv-ex10_15.htm) |  | 10-Q | 001-34375 | 10.15 | 08/14/2025 |
| 99.2 | [Form of Stock Unit Agreement under the 2020 Stock Incentive Plan](d19333dex992.htm) | X |  |  |  |  |
| 99.3 | [Form of Notice of Grant and Stock Option Agreement under the 2020 Stock Incentive Plan](http://www.sec.gov/Archives/edgar/data/1095981/000156459022006708/pstv-ex1026_110.htm) |  | 10-K | 001-34375 | 10.26 | 02/24/2022 |
| 99.4 | [2015 New Employee Incentive Plan](http://www.sec.gov/Archives/edgar/data/1095981/000109598116000038/ex10_1.htm) |  | 8-K | 001-34375 | 10.1 | 01/05/2016 |
| 99.5 | [First Amendment to the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan, dated January 26, 2017](http://www.sec.gov/Archives/edgar/data/1095981/000156459017005251/cytx-ex1042_653.htm) |  | 10-K | 001-34375 | 10.42 | 03/24/2017 |
| 99.6 | [Second Amendment to the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan, Dated February 6, 2020](http://www.sec.gov/Archives/edgar/data/1095981/000156459020014165/pstv-ex1025_203.htm) |  | 10-K | 001-34375 | 10.25 | 03/30/2020 |
| 99.7 | [Third Amendment to the 2015 New Employee Incentive Plan](http://www.sec.gov/Archives/edgar/data/1095981/000119312524157500/d840996dex1015.htm) |  | S-1 | 333-280061 | 10.15 | 06/07/2024 |
| 99.8 | [Form of Stock Option Agreement under the 2015 New Employee Incentive Plan](http://www.sec.gov/Archives/edgar/data/1095981/000109598116000054/formofstock.htm) |  | S-8 | 333-210211 | 99.4 | 03/15/2016 |
| 107 | [Filing Fee Table](d19333dexfilingfees.htm) | X |  |  |  |  |

---

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Houston, Texas, on August 22, 2025.

---

| | | |
|:---|:---|:---|
| **PLUS THERAPEUTICS, INC.** | **PLUS THERAPEUTICS, INC.** | **PLUS THERAPEUTICS, INC.** |
| By: | /s/ MARC H. HEDRICK, M.D. | /s/ MARC H. HEDRICK, M.D. |
|  | Name: | Marc H. Hedrick, M.D |
|  | Title: | President and Chief Executive Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Marc H. Hedrick, M.D and Andrew Sims, and each of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and revocation, in his or her name and on his or her behalf, to do any and all acts and things and execute, in the name of the undersigned, any and all instruments which said attorney-in-fact and agent may deem necessary or advisable to enable the Registrant to comply with the Securities Act, and any rules, regulations, or requirements of the Commission in respect thereof, in connection with the filing with the Commission of this Registration Statement under the Securities Act, including specifically but without limitation, power and authority to sign the name of the undersigned to such Registration Statement, and any amendments to such Registration Statement (including post-effective amendments), and to file the same with all exhibits thereto and other documents in connection therewith, with the Commission and any applicable securities exchange or securities regulatory body, to sign any and all applications, registration statements, notices or other documents necessary or advisable to comply with applicable securities laws, including without limitation state securities laws, and to file the same, together with other documents in connection therewith with the appropriate authorities, including without limitation state securities authorities, granting unto said attorney-in-fact and agent, full power and authority to do and to perform each and every act and thing requisite or necessary to be done in and about the premises, as fully and to all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute, may lawfully do or cause to be done by virtue hereof. This Power of Attorney may be signed in several counterparts.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities set forth below on August 22, 2025.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /S/ MARC H. HEDRICK, M.D.<br> MARC H. HEDRICK, M.D. | President, Chief Executive Officer and Director<br>*(Principal Executive Officer)* | August 22, 2025 |
| /S/ ANDREW SIMS<br> ANDREW SIMS | Chief Financial Officer<br>*(Principal Financial and Accounting Officer)* | August 22, 2025 |
| /S/ RICHARD J. HAWKINS<br> RICHARD J. HAWKINS | Chair of the Board of Directors | August 22, 2025 |
| /S/ HOWARD CLOWES<br> HOWARD CLOWES | Director | August 22, 2025 |
| /S/ AN VAN ES-JOHANSSON, M.D.<br> AN VAN ES-JOHANSSON, M.D. | Director | August 22, 2025 |
| /S/ ROBERT LENK, PH.D<br> ROBERT LENK, PH.D | Director | August 22, 2025 |
| /S/ KYLE GUSE<br> KYLE GUSE | Director | August 22, 2025 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g19333g0822073430824.jpg)

August 22, 2025

Plus Therapeutics, Inc.

2710 Reed Road, Suite 160

Houston, Texas 77002

Re: <u>Plus Therapeutics, Inc. Registration Statement on Form S-8</u>

Ladies and Gentlemen:

In connection with the registration under the Securities Act of 1933, as amended (the "Act"), by Plus Therapeutics, Inc., a Delaware corporation (the "Company"), of 20,075,000 shares (the "Registered Shares") of its common stock, par value $0.001 per share (the "Common Stock"), consisting of (i) 20,000,000 shares of Common Stock that are to be offered and may be issued under the Company's Fifth Amended and Restated 2020 Stock Incentive Plan (the "2020 Plan"), and (ii) 75,000 shares of Common Stock issuable pursuant to the Company's 2015 New Employee Incentive Plan (as amended, the "2015 Plan," and together with the 2020 Plan, the "Plans"), the following opinion is furnished to you to be filed with the Securities and Exchange Commission (the "Commission") as Exhibit 5.1 to the Company's Registration Statement on Form S-8 (the "Registration Statement") under the Act.

We have acted as counsel to the Company in connection with the Registration Statement, and we have examined originals or copies, certified or otherwise identified to our satisfaction, of the Registration Statement, the Certificate of Incorporation of the Company as amended and as presently in effect, the amended and restated bylaws of the Company, minute books and corporate records of the Company, and such other documents as we have considered necessary in order to furnish the opinion hereinafter set forth.

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all signatories to such documents. Other than our examination of the documents indicated above, we have made no other examination in connection with this opinion.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

Based on and subject to the foregoing, we are of the opinion that, when issued in accordance with the terms of the respective Plans and the options or other awards granted thereunder, the Registered Shares will be duly authorized, validly issued, fully paid and nonassessable shares of Common Stock.

This opinion speaks only as of the date hereof and we assume no obligation to update or supplement this opinion if any applicable laws change after the date of this opinion letter or if we become aware after the date of this opinion letter of any facts, whether existing before or arising after the date hereof, that might change the opinions expressed above.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we come within the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Commission promulgated thereunder.

---

| |
|:---|
|  Very truly yours, |
|  /s/ Sullivan & Worcester LLP |
|  SULLIVAN & WORCESTER LLP |

---

![LOGO](g19333g0822073431038.jpg)

## Exhibit 23.2

**Exhibit 23.2** 

<u>Consent of Independent Registered Public Accounting Firm</u> 

We hereby consent to the incorporation by reference in this Registration Statement of our report dated March 31, 2025, relating to the consolidated financial statements of Plus Therapeutics, Inc. (the Company) appearing in the Company's Annual Report on Form 10-K for the year ended December 31, 2024. Our report contains an explanatory paragraph regarding the Company's ability to continue as a going concern.

/s/ BDO USA, P.C.

Austin, Texas

August 22, 2025

## Exhibit 99.2

**Exhibit 99.2** 

**PLUS THERAPEUTICS, INC.** 

**2020 STOCK INCENTIVE PLAN** 

**Stock Unit Agreement** 

This Stock Unit Agreement and the associated grant award information (the "Customizing Information"), which Customizing Information is provided in written form or is available in electronic form from the recordkeeper for the Plus Therapeutics, Inc. 2020 Stock Incentive Plan, as amended and in effect from time to time (the "Plan"), is made as of the date shown as the "Grant Date" in the Customizing Information (the "Grant Date") by and between Plus Therapeutics, Inc., a Delaware corporation (the "Company"), and the individual identified in the Customizing Information (the "Recipient"). This instrument and the Customizing Information are collectively referred to as the "Stock Unit Agreement."

WITNESSETH THAT:

WHEREAS, the Company has instituted the Plan; and

WHEREAS, the Committee has authorized the grant of Stock Units with respect to the Company's Stock upon the terms and conditions set forth below and pursuant to the Plan, a copy of which is incorporated herein; and

WHEREAS, the Recipient acknowledges that he or she has carefully read this Stock Unit Agreement and agrees, as provided in Section 16(a) below, that the terms and conditions of the Stock Unit Agreement reflect the entire understanding between himself or herself and the Company regarding this Award of Stock Units (and the Recipient has not relied upon any statement or promise other than the terms and conditions of the Stock Unit Agreement with respect to this Award of Stock Units);

NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Recipient agree as follows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Grant</u>. Subject to the terms of the Plan and this Stock Unit Agreement, the Company hereby grants to the Recipient that number of Stock Units ("SUs") equal to the corresponding number of shares of the Company's Stock (the "Underlying Shares") shown in the Customizing Information under "Stock Units Granted."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Vesting</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>In General</u>. As long as the Recipient remains in an employment or contractual or other service relationship, as applicable (the "Relationship"), with the Company as of a "Vesting Date," as specified in the Customizing Information, and the Recipient as of such date is not in violation of any confidentiality, inventions, non-solicitation and/or non-competition agreement with the Company (each to the extent not otherwise prohibited under applicable state law), all or a portion, as applicable (the "Incremental Amount," as specified in the Customizing Information), of the SUs shall vest on such date. For the avoidance of doubt, except as otherwise provided pursuant to the terms of the Plan and Section 2(b), if the Recipient's Relationship with the Company is terminated by the Company or by the Recipient for any reason, whether voluntarily or involuntarily, no SUs granted pursuant to this Stock Unit Agreement shall vest under any circumstances on and after the date of such termination.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Committee Discretion</u>. In the event the Relationship is terminated for any reason (whether voluntary or involuntary), (i) the Recipient's right to vest in the SUs will, except as otherwise explicitly provided in this Section 2(b) or as provided by the Committee, terminate as of the date of the termination of the Relationship (and will not be extended by any notice period mandated under local law) and (ii) the Committee shall have the exclusive discretion to determine when the Relationship has terminated for purposes of this Stock Unit Agreement (including when the Recipient is no longer considered to be providing active service while on a leave of absence). Notwithstanding the preceding sentence, in the event of the Recipient's death or Disability, any unvested portion of this SU shall become fully vested.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Special Definitions</u>. For purposes of this Section 2, the term "Company" refers to the Company and any Parent, Subsidiary or Affiliate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Dividends</u>. If so provided in the Customizing Information, a Recipient shall be credited with dividend equivalents equal to the dividends the Recipient would have received if the Recipient had been the actual record owner of the Underlying Shares on each dividend record date on or after the Grant Date and through the date the Recipient receives a settlement pursuant to Section 4 below (the "Dividend Equivalent"). If a dividend on the Stock is payable wholly or partially in Stock, the Dividend Equivalent representing that portion shall be in the form of additional SUs, credited on a one-for-one basis. If a dividend on the Stock is payable wholly or partially in cash, the Dividend Equivalent representing that portion shall also be in the form of cash and a Recipient shall be treated as being credited with any cash dividends, without earnings, until settlement pursuant to Section 4 below. If a dividend on Stock is payable wholly or partially in other than cash or Stock, the Committee may, in its discretion, provide for such Dividend Equivalents with respect to that portion as it deems appropriate under the circumstances. Dividend Equivalents shall be subject to the same terms and conditions as the SUs originally awarded pursuant to this Stock Unit Agreement, and they shall vest (or, if applicable, be forfeited) as if they had been granted at the same time as the original SUs. Dividend Equivalents representing the cash portion of a dividend on Stock shall be settled in cash.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Delivery of Underlying Shares or Cash Settlement</u>. With respect to any SUs that become vested SUs as of a Vesting Date pursuant to Section 2, the Company shall issue and deliver to the Recipient as soon as practicable following the applicable Vesting Date (a) the number of Underlying Shares equal to the number of SUs vesting on that date or an amount of cash equal to the Fair Market Value, as defined in the Plan, of such Underlying Shares as of that date (or such later delivery date, if applicable) and (b) the amount (and in the form) due with respect to the Dividend Equivalents applicable to such Underlying Shares. Whether Underlying Shares, or the cash value thereof, shall be issued or paid at settlement shall be determined by the Committee based on the "Form of Settlement" specified in the Customizing Information.

------

To the extent the vesting of any RSUs occurs during a "blackout" period wherein certain employees, including the Recipient, are precluded from selling Stock, the Committee retains the right, in its sole discretion, to defer the delivery of the Underlying Shares; provided, however, that the Committee shall not exercise its right to defer the Recipient's receipt of the Underlying Shares if the Stock is specifically covered by a Rule 10b5-1 trading plan of the Recipient that causes the Stock to be exempt from any applicable blackout period then in effect. In the event the receipt of any shares of Stock is deferred hereunder due to the existence of a blackout period, the shares shall be issued to the Recipient on the first day following the termination of the blackout period; provided, however, that in no event shall the issuance of the shares be deferred later than the fifteenth day of the third month following the close of the year in which the Underlying Shares otherwise would have been issued.

Any shares issued pursuant to this Stock Unit Agreement shall be issued, without issue or transfer tax, by (i) delivering a stock certificate or certificates for such shares out of theretofore authorized but unissued shares or treasury shares of its Stock as the Company may elect or (ii) issuance of shares of its Stock in book entry form; provided, however, that the time of such delivery may be postponed by the Company for such period as may be required for it with reasonable diligence to comply with any applicable requirements of law. Notwithstanding the preceding provisions of this Section 4, delivery of Underlying Shares shall be made, or the amount of cash equivalent thereto shall be paid, only if the required purchase price designated as the "Purchase Price" shown in the Customizing Information per underlying SU is paid to the Company by means of payment acceptable to the Company in accordance with the terms of the Plan. If the Recipient fails to pay for or accept delivery of all of the shares, the right to shares of Stock provided pursuant to this Stock Unit Agreement may be terminated by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Withholding Taxes</u>. The Recipient hereby agrees, as a condition of this award, to provide to the Company (or a subsidiary employing the Recipient, as applicable) an amount sufficient to satisfy the Company's and/or subsidiary's obligation to withhold any and all federal, state, local or provincial income tax, social security, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items or statutory withholdings related to the Recipient's participation in the Plan (the "Withholding Amount"), if any, by (a) authorizing the Company and/or any subsidiary employing the Recipient, as applicable, to withhold the Withholding Amount from the Recipient's cash compensation or (b) remitting the Withholding Amount to the Company (or a subsidiary employing the Recipient, as applicable) in cash; provided, however, that to the extent that the Withholding Amount is not provided by one or a combination of such methods, the Company may at its election withhold from the Underlying Shares and Dividend Equivalents that would otherwise be delivered that number of shares (and/or cash) having a Fair Market Value on the date of vesting sufficient to eliminate any deficiency in the Withholding Amount. Regardless of any action that the Company and/or subsidiary takes with respect to any or all federal, state, local or provincial income tax, social security, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items or statutory withholdings related to the Recipient's participation in the Plan, the Recipient acknowledges that he or she, and not the Company and/or any subsidiary, has the ultimate liability for any such items. Further, if the Recipient becomes subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable or tax withholding event, the Recipient acknowledges that the Company and/or subsidiary may be required to withhold or account for such tax-related items in more than one jurisdiction.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Non-assignability of SUs and Dividend Equivalents</u>. The SUs and Dividend Equivalents shall not be assignable or transferable by the Recipient except by will or by the laws of descent and distribution or as permitted by the Committee in its discretion pursuant to the terms of the Plan. During the life of the Recipient, delivery of shares of Stock or payment of cash as settlement of the SUs and Dividend Equivalents shall be made only to the Recipient, to a conservator or guardian duly appointed for the Recipient by reason of the Recipient's incapacity or to the person appointed by the Recipient in a durable power of attorney acceptable to the Company's counsel.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Compliance with Securities Act; Lock-Up Agreement</u>. The Company shall not be obligated to sell or issue any Underlying Shares or other securities in settlement of the SUs and Dividend Equivalents hereunder unless the shares of Stock or other securities are at that time effectively registered or exempt from registration under the Securities Act and applicable state or provincial securities laws. In the event shares or other securities shall be issued that shall not be so registered, the Recipient hereby represents, warrants and agrees that the Recipient will receive such shares or other securities for investment and not with a view to their resale or distribution, and will execute an appropriate investment letter satisfactory to the Company and its counsel. The Recipient further hereby agrees that as a condition to the settlement of the SUs and Dividend Equivalents, the Recipient will execute an agreement in a form acceptable to the Company to the effect that the shares shall be subject to any underwriter's lock-up agreement in connection with a public offering of any securities of the Company that may from time to time apply to shares held by officers and employees of the Company, and such agreement or a successor agreement must be in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Legends</u>. The Recipient hereby acknowledges that the stock certificate or certificates (or entries in the case of book entry form) evidencing shares of Stock or other securities issued pursuant to any settlement of an SU or Dividend Equivalent hereunder may bear a legend (or provide a restriction) setting forth the restrictions on their transferability described in Section 7 hereof, if such restrictions are then in effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Rights as Stockholder</u>. The Recipient shall have no rights as a stockholder with respect to any SUs, Dividend Equivalents or Underlying Shares until the date of issuance of a stock certificate (or appropriate entry is made in the case of book entry form) for Underlying Shares and any Dividend Equivalents. Except as provided by Section 3, no adjustment shall be made for any rights for which the record date is prior to the date such stock certificate is issued (or appropriate entry is made in the case of book entry form), except to the extent the Committee so provides, pursuant to the terms of the Plan and upon such terms and conditions it may establish.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>Effect Upon Employment and Performance of Services</u>. Nothing in this Stock Unit Agreement or the Plan shall be construed to impose any obligation upon the Company or any subsidiary to employ or utilize the services of the Recipient or to retain the Recipient in its employ or to engage or retain the services of the Recipient.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. <u>Time for Acceptance</u>. Unless the Recipient shall evidence acceptance of this Stock Unit Agreement by electronic or other means prescribed by the Committee within sixty (60) days after its delivery, the SUs and Dividend Equivalents shall be null and void (unless waived by the Committee).

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. <u>Right of Repayment</u>. In the event that the Recipient breaches any confidentiality, inventions, non-solicitation and/or non-competition agreement with the Company, the Recipient shall pay to the Company an amount equal to the excess of the Fair Market Value of the Underlying Shares as of the date of settlement (whether settled in cash or Stock) over the Purchase Price, if any, paid (or deemed paid) together with the value of any Dividend Equivalents; provided, however, that the Committee in its discretion may release the Recipient from the requirement to make such payment, if the Committee determines that the Recipient's breach of such agreement is not inimical to the best interests of the Company. In accordance with applicable law, the Company may deduct the amount of payment due under the preceding sentence from any compensation or other amount payable by the Company to the Recipient. For purposes of this Section 12, the term "Company" refers to the Company and any Parent, Subsidiary or Affiliate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. <u>Section</u> <u>409A of the Internal Revenue Code</u>. The SUs and Dividend Equivalents granted hereunder are intended to avoid the potential adverse tax consequences to the Recipient of Section 409A of the Code and the Committee may make such modifications to this Stock Unit Agreement as it deems necessary or advisable to avoid such adverse tax consequences. If and to the extent that the SUs and Dividend Equivalents are subject to Section 409A, any payment upon termination of the Relationship shall be made only upon a "separation from service" under Section 409A and following any delay required by Treas. Reg. § 1.409A-3(i)(2), and the Recipient may not directly or indirectly designate the calendar year of a payment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. <u>Electronic Delivery</u>. The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Recipient consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. <u>Company Policies</u>. The SUs shall be subject to any applicable clawback or recoupment policies, share trading policies, and other policies that may be implemented by the Board from time to time, in accordance with applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. <u>General Provisions</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Amendment; Waivers</u>. This Stock Unit Agreement, including the Plan, contains the full and complete understanding and agreement of the parties hereto as to the subject matter hereof, and except as otherwise permitted by the express terms of the Plan and this Stock Unit Agreement and applicable law, it may not be modified or amended nor may any provision hereof be waived without a further written agreement duly signed by each of the parties; provided, however, that a modification or amendment that does not materially diminish the rights of the Recipient hereunder, as they may exist immediately before the effective date of the modification or amendment, shall be effective upon written notice of its provisions to the Recipient, to the extent permitted by applicable law. The waiver by either of the parties hereto of any provision hereof in any instance shall not operate as a waiver of any other provision hereof or in any other instance. The Recipient shall have the right to receive, upon request, a written confirmation from the Company of the Customizing Information.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Binding Effect</u>. This Stock Unit Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective heirs, executors, administrators, representatives, successors and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Fractional SUs, Underlying Shares and Dividend Equivalents</u>. All fractional Underlying Shares and Dividend Equivalents settled in Stock resulting from the application of the Vesting Schedule or the adjustment provisions contained in the Plan shall be rounded down to the nearest whole share. If cash in lieu of Underlying Shares is delivered at settlement, or Dividend Equivalents are settled in cash, the amount paid shall be rounded down to the nearest penny.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Governing Law</u>. This Stock Unit Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the principles of conflicts of law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <u>Construction</u>. This Stock Unit Agreement is to be construed in accordance with the terms of the Plan. In case of any conflict between the Plan and this Stock Unit Agreement, the Plan shall control. The titles of the sections of this Stock Unit Agreement and of the Plan are included for convenience only and shall not be construed as modifying or affecting their provisions. The masculine gender shall include both sexes; the singular shall include the plural and the plural the singular unless the context otherwise requires. Capitalized terms not defined herein shall have the meanings given to them in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <u>Language</u>. If the Recipient receives this Stock Unit Agreement, or any other document related to the SUs and/or the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <u>Data Privacy</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Recipient hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic
or other form, of the Recipient's personal data as described in this Stock Unit Agreement by and among, as applicable, his or her employer, the Company and its subsidiaries for the exclusive purpose of implementing, administering and managing
the Recipient's participation in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Recipient understands that his or her employer, the Company and its subsidiaries, as applicable, hold
certain personal information about the Recipient regarding his or her employment, the nature and amount of the Recipient's compensation and the fact and conditions of the Recipient's participation in the Plan, including, but not limited
to, the Recipient's name, home address, telephone number and e-mail address, date of birth, social insurance number or other identification number, salary, nationality, job title, any shares of stock or
directorships held in the Company and its subsidiaries, details of all options, awards or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Recipient's favor, for the purpose of
implementing, administering and managing the Plan (the "Data").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The Recipient understands that the Data may be transferred to any third parties assisting in the
implementation, administration and management of the Plan, that these third parties may be located in the Recipient's country, or elsewhere, and that the third party's country may have different data privacy laws and protections than the
Recipient's country. The Recipient understands that the Recipient may request a list with the names and addresses of any potential recipients of the Data by contacting his or her local human resources representative. The Recipient authorizes
the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing the Recipient's participation in the Plan, including any requisite transfer of
such Data as may be required to a broker or other third party. The Recipient understands that the Data will be held only as long as is necessary to implement, administer and manage Recipient's participation in the Plan. The Recipient
understands that he or she may, at any time, view the Data, request additional information about the storage and processing of the Data, require any necessary amendments to the Data or refuse or withdraw the consents herein, in any case without
cost, by contacting in writing the Recipient's local human resources representative. The Recipient understands, however, that refusing or withdrawing his or her consent may affect the Recipient's ability to participate in the Plan. For
more information on the consequences of refusal to consent or withdrawal of consent, the Recipient understands that the Recipient may contact his or her local human resources representative.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <u>Notices</u>. Any notice in connection with this Stock Unit Agreement shall be deemed to have been properly delivered if it is delivered in the form specified by the Committee as follows:

To the Recipient: Last address provided to the Company

To the Company: Plus Therapeutics, Inc.

2710 Reed Road, Suite 160

Houston, Texas 77002

Attn: Chief Financial Officer

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <u>Version Number</u>. This document is Version 1 of the Plus Therapeutics, Inc. 2020 Stock Incentive Plan Stock Unit Agreement.

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**PLUS THERAPEUTICS, INC.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common Shares, par value $0.001 per share | Other | 20075000 | $0.49 | $9836750.00 | 0.0001531 | $1506.01 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $9836750.00  |  | $1506.01  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $1506.01  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $0.00  |

---

 **Offering Note** <br>

<sup>1</sup> (1) This Registration Statement on Form S-8 (the "Registration Statement") registers the issuance of 20,075,000 shares of common stock, par value $0.001 per share ("Common Stock"), of Plus Therapeutics, Inc., consisting of (i) 20,000,000 shares of Common Stock issuable pursuant to the Fifth Amended and Restated Plus Therapeutics, Inc. 2020 Stock Incentive Plan, and (ii) 75,000 shares of Common Stock issuable pursuant to the Plus Therapeutics, Inc. 2015 New Employee Incentive Plan. (2) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers additional securities that may be offered as a result of stock splits, stock dividends or similar transactions. (3) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities Act. The offering price per share and the aggregate offering price are calculated using the average of the high and low prices per share for the Common Stock trading on Nasdaq on August 20, 2025, which date is within five business days prior to filing this Registration Statement.

---

| | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | | Registrant or Filer Name | Form or Filing Type | File Number | Initial Filing Date | Filing Date | Fee Offset Claimed | Security Type Associated with Fee Offset Claimed | Security Title Associated with Fee Offset Claimed | Unsold Securities Associated with Fee Offset Claimed | Unsold Aggregate Offering Amount Associated with Fee Offset Claimed | Fee Paid with Fee Offset Source |
| **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** | **Rule 457(p)** |
| Fee Offset Claims | 1, 2 | Plus Therapeutics, Inc. | S-3 | 333-286393 | 04/04/2025 |  | $1506.01 | Equity | Common Stock, par value $0.001 per share | 0 | $0.00 |  |
| Fee Offset Sources | 3 | Plus Therapeutics, Inc. | S-3 | 333-286393 |  | 04/04/2025 |  |  |  |  |  | $194082.78 |

---

 **Rule 457(p) Statement of Withdrawal, Termination, or Completion:** <br>

<sup>1</sup> The registrant withdrew the Source Registration Statement by filing a Form RW on June 23, 2025. <br>

 **Offset Note** <br>

<sup>2</sup> A filing fee of $194,082.78 was previously paid in connection with the registration statement on Form S-3 (No. 333-286393) filed by the registrant on April 4, 2025 (the "Source Registration Statement"). The registrant withdrew the Source Registration Statement by filing a Form RW on June 23, 2025. As the Source Registration Statement was not declared effective, no securities were sold thereunder. As a result, upon withdrawal of the Source Registration Statement, the registrant had $194,082.78 in unused filing fees. On August 12, 2025, the registrant filed a registration statement on Form S-1 (No. 333-289526), for which it offset $3,688.18 of the filing fees due in connection therewith by the unused filing fees previously paid by the Registrant in connection with the filing of the Source Registration Statement, resulting in $190,394.60 in remaining unused fees available to be applied to subsequent filings of the registrant. In accordance with Rule 457(p) of the Securities Act, such unused filing fees will offset the filing fee of $1,506.01 currently due pursuant to this Registration Statement. Accordingly, $188,888.59 of the unused filing fees previously paid in connection with the Source Registration Statement remain available to be used to offset the fees that may become due for future registration statements.

<sup>3</sup> A filing fee of $194,082.78 was previously paid in connection with the registration statement on Form S-3 (No. 333-286393) filed by the registrant on April 4, 2025 (the "Source Registration Statement"). The registrant withdrew the Source Registration Statement by filing a Form RW on June 23, 2025. As the Source Registration Statement was not declared effective, no securities were sold thereunder. As a result, upon withdrawal of the Source Registration Statement, the registrant had $194,082.78 in unused filing fees. On August 12, 2025, the registrant filed a registration statement on Form S-1 (No. 333-289526), for which it offset $3,688.18 of the filing fees due in connection therewith by the unused filing fees previously paid by the Registrant in connection with the filing of the Source Registration Statement, resulting in $190,394.60 in remaining unused fees available to be applied to subsequent filings of the registrant. In accordance with Rule 457(p) of the Securities Act, such unused filing fees will offset the filing fee of $1,506.01 currently due pursuant to this Registration Statement. Accordingly, $188,888.59 of the unused filing fees previously paid in connection with the Source Registration Statement remain available to be used to offset the fees that may become due for future registration statements.